Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Chen Y, et al. Among authors: duda dg. Hepatology. 2014 Apr;59(4):1435-47. doi: 10.1002/hep.26790. Epub 2014 Feb 18. Hepatology. 2014. PMID: 24242874 Free PMC article.
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. Chen Y, et al. Among authors: duda dg. Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20. Hepatology. 2015. PMID: 25529917 Free PMC article.
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Chen Y, et al. Among authors: duda dg. Sci Rep. 2017 Mar 9;7:44123. doi: 10.1038/srep44123. Sci Rep. 2017. PMID: 28276530 Free PMC article.
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG. Grassberger C, et al. Among authors: duda dg. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1222-1225. doi: 10.1016/j.ijrobp.2018.04.026. Epub 2018 Apr 17. Int J Radiat Oncol Biol Phys. 2018. PMID: 29859792 Free PMC article. Clinical Trial.
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. Goyal L, et al. Among authors: duda dg. Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6. Clin Cancer Res. 2019. PMID: 30190369 Free PMC article. Clinical Trial.
262 results